Seeking Alpha

Achillion Pharmaceuticals, Inc. (ACHN)

  • Dec. 24, 2014, 9:12 AM
    | Comment!
  • Dec. 24, 2014, 9:01 AM
    • Achillion Pharmaceuticals (NASDAQ:ACHN) is up 6% premarket on high volume in response to the prevailing opinion that yesterday's 24% plunge on 4x normal volume was overdone. The AbbVie/Express Scripts deal stoked the biotech/pharma sell-off.
    • Previously: Money flowing out of biotech today (Dec. 23)
  • Dec. 23, 2014, 12:45 PM
    | Comment!
  • Dec. 23, 2014, 10:49 AM
  • Dec. 22, 2014, 7:24 AM
    • In an open label Phase 2 proxy study, Achillion Pharmaceuticals' (NASDAQ:ACHN) NS5A inhibitor, ACH-3102, in combination with Sovaldi (sofosbuvir) achieved 100% SVR4 in 12 patients in six weeks, independent of baseline viral load, gender and IL28B status. SVR12 results will be reported in H1 2015. The combination therapy was well-tolerated with no serious adverse events reported.
    • In a Phase 1 proof-of-concept study in treatment-naive HCV-1 patients, the company's nucleotide inhibitor, ACH-3422, demonstrated a mean maximum reduction in HCV viral RNA load of 4.8 log10 IU/mL within 14 days at a dose of 700 mg (once daily for 14 days). Three of six patients achieved undetectable HCV RNA (<10 IU/mL).
    • The company will conduct a conference call this morning at 8:30 am ET to discuss the results.
    • Shares are up 62% premarket on robust volume.
  • Nov. 21, 2014, 8:48 AM
  • Nov. 13, 2014, 1:48 PM
    • Achillion Pharmaceuticals (ACHN -7.2%) drops on almost double normal volume as traders take some money off the table after the stock hit a 52-week high yesterday. Shares ballooned over five-fold from the early June breakout.
    • Previously: More good news for Achillion
  • Nov. 11, 2014, 11:03 AM
    • At The Liver Meeting in Boston, Gilead Sciences (GILD +1.1%) presented results from several Phase 2 and Phase 3 trials evaluating Harvoni (ledipasvir 90 mg/sofosbuvir 400 mg) for the treatment of chronic HCV infection in patients with limited or no treatment options, including decompensated cirrhosis, HCV recurrence following liver transplantation and patients refractory to other direct-acting antivirals.
    • In a pooled analysis of Phase 2 and Phase 3 open-label studies involving more than 500 HCV-1 patients with compensated cirrhosis who received Harvoni alone or with ribavirin (RBV) for 12 or 24 weeks, 96% achieved SVR12.
    • In a Phase 2 open-label study evaluating patients with decompensated cirrhosis and those with HCV recurrence after a liver transplant, 87% of those receiving Harvoni + RBV for 12 weeks achieved SVR12 compared to 89% of the treatment arm receiving a 24-week regimen (subgroup analysis of 108 HCV genotype 1 and 4 patients).
    • In another subgroup analysis from the same Phase 2 trial, response rates for patients who developed HCV (genotypes 1 and 4) recurrence following liver transplantation who were treated with Harvoni + RBV were analyzed. SVR12 rates for non-cirrhotic patients were 96% and 98%, respectively, for the 12- and 24-week regimens. For patients with compensated cirrhosis, the SVR12 rate was 96% for both regimens. For patients with decompensated cirrhosis, the SVR12 rate was 81% for both regimens.
    • In two studies of HCV patients who failed prior therapy, those receiving Harvoni + RBV for 12 weeks achieved SVR12 rates of 96% and 98%. Those receiving Harvoni alone for 24 weeks (Study GS-US-337-0121) achieved an SVR12 rate of 97%.
    • HCV-related tickers: (BMY -0.1%)(MRK +1.4%)(ABBV +0.3%)(JNJ +0.2%)(ACHN -0.6%)(RGLS -2.7%)(CNAT -1.1%)(ENTA -0.4%)
  • Nov. 11, 2014, 10:07 AM
    • At The Liver Meeting in Boston, AbbVie (ABBV -0.1%) presented results from studies in HCV patients co-infected with HIV and liver transplant recipients who received its all-oral, interferon-free investigational treatment combining three antivirals (ombitasvir/ABT-450/ritonavir and dasabuvir)
    • SVR12 rates for patients co-infected with HCV/HIV that received the company's investigational treatment plus ribavirin were 93.5% for the 12-week regimen and 90.6% for the 24-week regimen.
    • In non-cirrhotic liver transplant recipients with recurrent HCV-1 new to treatment, SVR12 and SVR24 rates were each 97.1%.
    • HCV-related tickers: (GILD +0.5%)(MRK +1%)(JNJ -0.1%)(BMY -0.2%)(ENTA +0.2%)(RGLS +0.2%)(CNAT -0.5%)(ACHN -1.7%)
    | 1 Comment
  • Nov. 11, 2014, 9:37 AM
    • At The Liver Meeting in Boston, Merck (NYSE:MRK) presented data from a Phase 2 clinical trial evaluating the combination of the company's investigational NS3/4A inhibitor, grazoprevir, and its investigational NS5A inhibitor, elbasvir, with and without ribavirin, in treatment-naive and treatment-experienced HCV-1 patients. The length of treatment was either eight,12 or 18 weeks.
    • SVR12 rates in treatment-naive non-cirrhotic patients were: 8-week regimen with RBV: 80%; 12-week regiment with and without RBV: 93% and 98%.
    • SVR12 rates in treatment-naive patients with cirrhosis were: 12-week regimen with and without RBV: 90% and 97%; 18-week regimen with and without RBV: 97% and 94%.
    • SVR12 rates for treatment-experienced patients with and without cirrhosis: 12-week regimen with and without RBV: 94% and 91%; 18-week regimen with and without RBV: 100% and 97%.
    • SVR12 rates for HCV-1 patients co-infected with HIV: 12-week regimen with and without RBV: 97% and 87%.
    • Results from a Phase 3 trial are expected in 1H 2015.
    • Previously: Merck triple therapy HCV candidate fails as a four-week regimen
    • HCV-related tickers: (GILD +0.4%)(JNJ -0.2%)(BMY -0.1%)(ABBV +0.3%)(ACHN +3%)(ENTA +0.4%)(CNAT)(LGND +0.5%)(RGLS)
  • Nov. 11, 2014, 9:05 AM
    • At The Liver Meeting in Boston, Gilead Sciences (NASDAQ:GILD) presented data from three Phase 2 studies evaluating an all-oral pan-genotypic regimen, Sovaldi (sofosbuvir) + the company's investigational NS5A inhibitor GS-5816, for the treatment of HCV infection. The specific regimens were Sovaldi 400 mg plus GS-5816 25 mg or 100 mg, with and without ribavirin, for eight or 12 weeks.
    • The first study, GS-US-342-0109, evaluated Sovaldi + GS5816 with and without ribavirin for 12 weeks in treatment-experienced HCV-1 and HCV-3 patients with and without cirrhosis. SVR12 rates: SOF + GS-5816 100 mg: 100% for GT1 with and without cirrhosis; 100% for GT3 without cirrhosis and 88% for GT3 with cirrhosis. SVR12 rates: SOF + GS-5816 + RBV: 100% for GT1 without cirrhosis and GT3 without cirrhosis; 90% in GT1 with cirrhosis and 96% in GT3 with cirrhosis.
    • The second study, ELECTRON 2, evaluated the same regimen as the first study for eight weeks in non-cirrhotic treatment-naive genotype 3 patients. The SVR12 rate inclusive of ribavirin was 100% and 96% for the ribavirin-free approach.
    • The third study, GS-US-342-0102, evaluated the same regimen as first study in non-cirrhotic treatment-naive patients. Results from Part A evaluating 12 weeks of treatment were presented at The International Liver Congress in April 2014. The results from Part B, presented this week, evaluated eight weeks of treatment in HCV-1 and HCV-2 patients. SVR12 rates were: G1: 81% and 90% with and without RBV; G2: 88% with and without RBV.
  • Nov. 10, 2014, 12:59 PM
    | 1 Comment
  • Nov. 10, 2014, 11:30 AM
    • Achillion Pharmaceuticals (ACHN +19.2%) jumps on a 2x surge in volume in response to its announcement over the weekend of 100% SVR12 in 12 HCV-1 patients in a Phase 2 pilot study of ACH-3102 in combination with Sovaldi (sofosbuvir).
    • Previously: Achillion presents HCV data at The Liver Meeting
  • Nov. 10, 2014, 9:14 AM
    | Comment!
  • Nov. 9, 2014, 5:06 PM
    • At this week's Annual Meeting for the Study of Liver Diseases in Boston, Achillion Pharmaceuticals (NASDAQ:ACHN) gave poster presentations on two of its HCV product candidates.
    • In a Phase 2 pilot study evaluating eight-week treatment of its NS5A inhibitor, ACH-3102, in combination with Sovaldi (sofosbuvir) in treatment-naive HCV genotype 1 patients, the interferon-free, ribavirin-free regimen demonstrated 100% SVR12 in 12 patients. SVR12 or sustained viral response 12 weeks after the completion of therapy, is considered cured. Sovaldi's SVR12 (in combination with peg-interferon alfa and ribavirin) is 90% for HCV-1. Harvoni's (sofosbuvir + ledipasvir) is 94 - 99%.
    • The company presented three posters on preclinical results for its uridine analog prodrug, ACH-3422. The data showed improved potency against HCV-3 compared to sofosbuvir. The combination of ACH-3422 with ACH-3102 or sovaprevir (Achillion's Phase 2 NS3/4A inhibitor) displayed additive synergistic activity in vitro. Also, ACH-3422, in combination with other direct-acting antiviral agents, demonstrated the ability to block the appearance of resistant colonies in vitro.
    • According to recent research, the global prevalence of HCV genotypes is: type 1: 46%; type 2: 13%; type 3: 22% and type 4: 13%.
  • Nov. 4, 2014, 6:35 AM
    • Achillion Pharmaceuticals (NASDAQ:ACHN): Q3 EPS of -$0.16 beats by $0.02.
    • Press Release
    | Comment!
ACHN vs. ETF Alternatives
Company Description
Achillion Pharmaceuticals Inc is a biopharmaceutical company which focuses on the discovery, development and commercialization of treatments for infectious diseases.
Sector: Healthcare
Industry: Biotechnology
Country: United States